September 14, 2015 9:16am
KITE will receive exclusive option to license multiple T cell receptor gene sequences. KITE closed at $63.63 after Friday’s surge of +$2.48.
Members only. Please login.
September 14, 2015 9:16am
KITE will receive exclusive option to license multiple T cell receptor gene sequences. KITE closed at $63.63 after Friday’s surge of +$2.48.
Members only. Please login.
35 companies, 1 interpreter!
Insight, foresight and recommendation
20 min ago
RegMedInvestors (RMi) Finance note: Prime Medicine (PRME) closes 43.7 M share offering at $3.30
29 min ago
RegMed Investors (RMi) Closing Bell: Feet wet
8 hours 55 min ago
RegMed Investors’ (RMi) pre-open: “Never get out of the boat”
8 hours 55 min ago
RegMed Investors’ (RMi) pre-open: “Never get out of the boat”
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.